Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00848926 · OUTCOME

Time of Maximum Serum Concentration

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma · Source last updated 2017-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
3 weeks

What was measured

Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Analysis population: All participants who received treatment

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin102

Reported measurements

Source class 1
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin0.02Not reported0.020.02Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.02
        upper Limit
        0.02
        value
        0.02
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin
dispersion Type
Full Range
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
MEDIAN
population Description
All participants who received treatment
reporting Status
POSTED
time Frame
3 weeks
title
Time of Maximum Serum Concentration
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice